Fig. 4.
Sacubitril/valsartan (sac/val) ameliorates in vivo aortic stiffening, as well as endothelial stiffening in ex vivo aortic explants. a Pulse wave velocity (PWV) measured after 10 weeks of treatment. N = 6, 5, 5, and 7 for ZOC, ZOSV, ZOV and ZOH, respectively. b Force measurements were acquired by interaction between a cantilever tip and the EC surface of aortic explants from rats after 10 weeks of treatment. N = 4, 4, 4, 5 and 3 for ZOC, ZOSV, ZOV and ZOH, respectively. c Sac/val (▼) and val (○) treatments prevent impaired responses to the nitric oxide dependent vasodilator, acetylcholine in aortic rings of ZO rats (○). Note the normal reactivity of in ZLC aortae (●). Data are represented by means ± SE in the accompanying bar graph. N = 3, 8, 8, 7 and 7 for ZLC, ZOC, ZOSV, ZOV and ZOH, respectively. Symbols: *Indicates p < 0.05 versus ZLC; †Indicates p < 0.05 versus ZOC; indicates §p < 0.05 versus ZOH